Lymphomes de l’Adulte . J Clin Oncol 1997 ; 15 : 1110 – 1117 . 3. Ardeshna KM Smith P Norton A . Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised
Richard I. Fisher and Nadia Khan
Caron A. Jacobson and Arnold S. Freedman
untreated low-grade non-Hodgkin’s lymphomas . N Engl J Med 1984 ; 311 : 1471 – 1475 . 3. Ardeshna KM Smith P Norton A . Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non
Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff and Hannah M. Linden
select for cells with high ER expression. In this case report, the imaging studies were observational and not used for treatment decision-making. Nevertheless, these results confirm temporal heterogeneity of ER expression over the course of systemic
Donna Trauth and Lori J. Goldstein
therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women . N Engl J Med 1988 ; 319 : 1681 – 1692 . 3 Early Breast Cancer Trialists' Collaborative Group . Systemic treatment of early breast cancer by
Piet Dirix, Lynda Wyld, Shani Paluch-Shimon and Philip Poortmans
benefits from a clinical trial or indeed any systemic treatment, whereas a similar patient at the fifth line of therapy might be expected to benefit substantially less. Still, replacing PS with an alternative that is straightforward but more objective is
Henry G. Kaplan, Steven Rostad, Jeffrey S. Ross, Siraj M. Ali and Sherri Z. Millis
Malignant peripheral nerve sheath tumors (MPNSTs) are rare tumors for which no established systemic treatment exists. MPNSTs occur in approximately 10% of patients with neurofibromatosis type 1, with malignancy usually present in the third or
Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb and William I. Gradishar
is made to confirm the diagnosis and tumor pathologic profile (estrogen receptor, progesterone receptor, and HER2 status). Systemic Treatment of Recurrent or Stage IV Disease Recommendations: The committee recommends administering adjuvant
Carol D. Morris
Osteosarcoma Group (EURAMOS) is randomizing postoperative systemic treatment to additional ifosfamide and etoposide, or interferon-α based on specimen necrosis. The benefit of this approach for treating patients with pelvic tumors is currently unknown
Annette M. Lim, Graham R. Taylor, Andrew Fellowes, Laird Cameron, Belinda Lee, Rodney J. Hicks, Grant A. McArthur, Christopher Angel, Benjamin Solomon and Danny Rischin
than 6 months. From a molecular perspective, TP53 mutations have been commonly reported in ATC, but given the lack of effective systemic treatment options for the disease, it has been of particular interest to note reports of the identification of
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead and Rashmi Kumar
predictive biomarkers by providing tumor specimens and blood samples before and during systemic treatment. Selection of Patients for Preoperative Therapy Not all patients are appropriate candidates for preoperative systemic therapy. According to the
